Research map: Menin inhibitors for adult acute myeloid leukemia: 2025 update

Back to the article

Papers in this map

  1. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia · The Cancer Genome Atlas Research Network · 2013 · 5260 citations · Cited by this paper
  2. Advancements in longevity pharmacology research – are we finally seeing clinical progression? · 2026 · Related
  3. Positional Cloning of the Gene for Multiple Endocrine Neoplasia-Type 1 · Settara C. Chandrasekharappa · 1997 · 2098 citations · Cited by this paper
  4. Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · 2025 · Related
  5. The diverse functions of histone lysine methylation · Cyrus C. Martin · 2005 · 2070 citations · Cited by this paper
  6. Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · 2025 · Related
  7. The Mammalian Epigenome · B Bernstein · 2007 · 2067 citations · Cited by this paper
  8. The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates · 2026 · Related
  9. The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis · Akihiko Yokoyama · 2005 · 698 citations · Cited by this paper
  10. Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates · 2026 · Related
  11. The roles of microRNAs in epigenetic regulation · Qian Yao · 2019 · 540 citations · Cited by this paper
  12. Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · 2025 · Related
  13. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia · Ghayas C. Issa · 2023 · 501 citations · Cited by this paper
  14. Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · 2026 · Related
  15. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia · Jolanta E. Grembecka · 2012 · 466 citations · Cited by this paper
  16. Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · 2026 · Related
  17. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance · Myriam Alcalay · 2005 · 364 citations · Cited by this paper
  18. A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug · 2026 · Related
  19. Mutant NPM1 Maintains the Leukemic State through HOX Expression · Lorenzo Brunetti · 2018 · 329 citations · Cited by this paper
  20. Menin: a scaffold protein that controls gene expression and cell signaling · Smita S. Matkar · 2013 · 295 citations · Cited by this paper
  21. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia · Hannah J. Uckelmann · 2020 · 278 citations · Cited by this paper
  22. MEN1 mutations mediate clinical resistance to menin inhibition · Florian Perner · 2023 · 265 citations · Cited by this paper
  23. The KMT2A recombinome of acute leukemias in 2023 · Claus Meyer · 2023 · 240 citations · Cited by this paper
  24. Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) · Ghayas C. Issa · 2024 · 232 citations · Cited by this paper
  25. Primary Role of the Nucleosome · Roger D. Kornberg · 2020 · 205 citations · Cited by this paper
  26. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology · Daniel Aaron Pollyea · 2023 · 200 citations · Cited by this paper
  27. Crystal Structure of Menin Reveals Binding Site for Mixed Lineage Leukemia (MLL) Protein · Marcelo J. Murai · 2011 · 111 citations · Cited by this paper
  28. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial · Eunice S. Wang · 2024 · 111 citations · Cited by this paper
  29. Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia · Masayuki Umeda · 2022 · 103 citations · Cited by this paper
  30. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements · Ghayas C. Issa · 2021 · 102 citations · Cited by this paper
  31. MLL/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis · Aamir Ali · 2017 · 101 citations · Cited by this paper
  32. Epigenetic drugs in cancer therapy · Amila Suraweera · 2025 · 98 citations · Cited by this paper
  33. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia · Anna Candoni · 2024 · 73 citations · Cited by this paper
  34. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias · Min Chul Kwon · 2024 · 70 citations · Cited by this paper
  35. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors · Juan Martin Barajas · 2023 · 64 citations · Cited by this paper
  36. NPM 1 Mutations in AML—The Landscape in 2023 · Naman Sharma · 2023 · 53 citations · Cited by this paper
  37. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML · Ghayas C. Issa · 2024 · 50 citations · Cited by this paper
  38. Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia · Joshua F. Zeidner · 2024 · 43 citations · Cited by this paper
  39. Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations · Emma J Searle · 2024 · 39 citations · Cited by this paper

Source: OpenAlex (CC0)